Publications

• NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro.
  Int J Mol Sci Volume: 26
  02/18/2025 Authors: Lee KJ; Chokshi S; Joshi T; Cummings M; Lyons CE; Singleton MH; Catranis E; Madiera da Silva L; Hayat F; Migaud M
• Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
  Cancer Volume: 131 Page(s): e35757
  02/15/2025 Authors: Duska LR; Petroni GR; Thaker PH; Crane EK; Holman LL; Armstrong DK; Romano K; Scalici J
• A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.
  Clin Cancer Res Volume: 31 Page(s): 308 - 315
  01/17/2025 Authors: Chae YK; Corthell L; Patel SP; Edwards R; Scalici JM; Kim HS; Chung LI-Y; Othus M; McLeod CM; Chen HX
• A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
  Gynecol Oncol Volume: 188 Page(s): 13 - 21
  09/01/2024 Authors: Wilhite AM; Wu S; Xiu J; Gibney GT; Phung T; In GK; Herzog TJ; Khabele D; Erickson BK; Brown J
• A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
  Int J Gynecol Cancer Volume: 33 Page(s): 1458 - 1463
  09/04/2023 Authors: Holloway RW; Thaker P; Mendivil AA; Ahmad S; Al-Niaimi AN; Barter J; Beck T; Chambers SK; Coleman RL; Crafton SM
• Phosphodiesterase 10A (PDE10A) as a novel target to suppress -catenin and RAS signaling in epithelial ovarian cancer.
  J Ovarian Res Volume: 15 Page(s): 120
  11/02/2022 Authors: Borneman RM; Gavin E; Musiyenko A; Richter W; Lee KJ; Crossman DK; Andrews JF; Wilhite AM; McClellan S; Aragon I
• The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.
  Gynecol Oncol Volume: 166 Page(s): 417 - 424
  09/01/2022 Authors: Leitao MM; Zhou QC; Brandt B; Iasonos A; Sioulas V; Lavigne Mager K; Shahin M; Bruce S; Black DR; Kay CG
• A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
  Gynecol Oncol Volume: 164 Page(s): 181 - 186
  01/01/2022 Authors: Rocconi RP; Wilhite AM; Schambeau L; Scalici J; Pannell L; Finan MA
• Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers.
  Int J Gynecol Cancer Volume: 31 Page(s): 1403 - 1407
  11/01/2021 Authors: Grette KV; White AL; Awad EK; Scalici JM; Young-Pierce J; Rocconi RP; Jones NL
• Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
  Cancer Volume: 126 Page(s): 4948 - 4956
  11/15/2020 Authors: Duska LR; Scalici JM; Temkin SM; Schwarz JK; Crane EK; Moxley KM; Hamilton CA; Wethington SL; Petroni GR; Varhegyi NE
• Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity.
  Gynecol Oncol Volume: 157 Page(s): 729 - 732
  06/01/2020 Authors: Awad E; Paladugu R; Jones N; Pierce JY; Scalici J; Hamilton CA; Darcy KM; Maxwell GL; Rocconi RP
• HPV vaccination, knowledge, and attitudes among young cervical cancer survivors in the Deep South.
  Vaccine Volume: 37 Page(s): 550 - 557
  01/21/2019 Authors: Edler M; Fernandez A; Anderson K; Pierce JY; Scalici J; Daniel CL
• Should Self-Sampling Be an Option for Women in the United States?
  J Low Genit Tract Dis Volume: 23 Page(s): 54 - 57
  01/01/2019 Authors: Jeronimo J; Perkins RB; Scalici J; Pierce JY
• RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
  Oncogene Volume: 36 Page(s): 6680 - 6690
  11/30/2017 Authors: Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP
• MicroRNAs in gynecological cancers: Small molecules with big implications.
  Cancer Lett Volume: 407 Page(s): 123 - 138
  10/28/2017 Authors: Srivastava SK; Ahmad A; Zubair H; Miree O; Singh S; Rocconi RP; Scalici J; Singh AP
• Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
  Cancer Volume: 123 Page(s): 977 - 984
  05/15/2017 Authors: Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
• Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
  Gynecol Oncol Volume: 145 Page(s): 329 - 333
  05/01/2017 Authors: Ross J; Braswell KV; Madeira da Silva L; Mujica F; Stutsman S; Finan MA; Nicolson W; Harmon MD; Missanelli M; Cohen A
• A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
  Lancet Oncol Volume: 18 Page(s): 384 - 392
  03/01/2017 Authors: Rossi EC; Kowalski LD; Scalici J; Cantrell L; Schuler K; Hanna RK; Method M; Ade M; Ivanova A; Boggess JF
• Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.
  Biochem Biophys Res Commun Volume: 469 Page(s): 449 - 455
  01/15/2016 Authors: Somasagara RR; Tripathi K; Spencer SM; Clark DW; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Piazza GA; Palle K
• Minority participation in Gynecologic Oncology Group (GOG) Studies.
  Gynecol Oncol Volume: 138 Page(s): 441 - 444
  08/01/2015 Authors: Scalici J; Finan MA; Black J; Harmon MD; Nicolson W; Lankes HA; Brady WE; Rocconi RP
• Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation.
  Oncotarget Volume: 6 Page(s): 5237 - 5252
  03/10/2015 Authors: Tripathi K; Hussein UK; Anupalli R; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Owen LB; Piazza GA; Palle K
• The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes.
  Gynecol Oncol Volume: 136 Page(s): 512 - 515
  03/01/2015 Authors: Scalici J; Laughlin BB; Finan MA; Wang B; Rocconi RP
• Validation of a venous thromboembolism risk assessment model in gynecologic oncology.
  Gynecol Oncol Volume: 134 Page(s): 160 - 163
  07/01/2014 Authors: Stroud W; Whitworth JM; Miklic M; Schneider KE; Finan MA; Scalici J; Reed E; Bazzett-Matabele L; Straughn JM; Rocconi RP
• Inhibition of 41 integrin increases ovarian cancer response to carboplatin.
  Gynecol Oncol Volume: 132 Page(s): 455 - 461
  02/01/2014 Authors: Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
• Para-aortic lymph node dissection for women with endometrial adenocarcinoma and intermediate- to high-risk tumors: does it improve survival?
  Int J Gynecol Cancer Volume: 24 Page(s): 91 - 96
  01/01/2014 Authors: Courtney-Brooks M; Scalici JM; Tellawi AR; Cantrell LA; Duska LR
• ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
  PLoS One Volume: 9 Page(s): e107142
  01/01/2014 Authors: Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K
• Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.
  J Nucl Med Volume: 54 Page(s): 1883 - 1889
  11/01/2013 Authors: Scalici JM; Thomas S; Harrer C; Raines TA; Curran J; Atkins KA; Conaway MR; Duska L; Kelly KA; Slack-Davis JK
• Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era.
  Gynecol Oncol Case Rep Volume: 5 Page(s): 6 - 9
  01/01/2013 Authors: Courtney-Brooks M; Scalici J; Henretta MS; Modesitt SC; Jazaeri AA; Cantrell LA; Duska LR
• Frailty: an outcome predictor for elderly gynecologic oncology patients.
  Gynecol Oncol Volume: 126 Page(s): 20 - 24
  07/01/2012 Authors: Courtney-Brooks M; Tellawi AR; Scalici J; Duska LR; Jazaeri AA; Modesitt SC; Cantrell LA